References
1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the
World Health Organization classification of myeloid neoplasms and acute
leukemia. Blood 2016; 127:2391-2405.
2. Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med 2019;
381: 2135-2144.
3. Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms.
Semin Thromb Hemost 2014; 40: 348-358.
4. Etheridge SL, Roh ME, cosgrove ME, et al. JAK2V617F-positive
endothelial cell contribute to clotting abnormalities in
myeloproliferative neoplasms. Proc Natl Acad Sci USA 2014; 111:
2295-2300.
5. Guy A, Gourdou-Latyszenok V, Lay NL, et al. Vascular endothelial cell
expression of JAK2V617F is sufficient to promote a pro-thrombotic state
due to increased P-selectin expression. Haematologica 2019; 104: 70-81
6. Poisson J, Tanguy M, Davy H, et al. Erythrocyte-derived microvesicles
induce arterial spasm in JAK2V617F myeloproliferative neoplasm. J Clin
Invest 2020; 130: 2630-2643.
7. Gugliotta L, Tieghi A, Tortorella G, et al. Low impact of
cardiovascular adverse events on anagrelide treatment discontinuation in
a cohort of 232 patients with essential thrombocythemia. Leuk Res 2011;
35: 1557-1563.
8. Tortorella G, Piccin A, Tieghi A, et al. Anagrelide treatment and
cardiovascular monitoring in essential thrombocythemia. A prospective
observational study. Leuk Res 2015; 39: 592-598.
9. Birgegard G, Besses C, Griesshammer M, et al. Treatment of essential
thrombocythemia in Europe: a prospective long-term observational study
of 3649 high-risk patients in the evaluation of anagrelide efficacy and
long-term safety study. Haematologica 2018; 103: 51-60.
10. Griesshammer M, Bangerter M, Vliet H, Michiels JJ. Aspirin in
essential thrombocythemia: Status Quo and Quo Vadis. Semin Thromb Hemost
1997; 23: 371-377.
11. De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients
with polycythemia vera and essential thrombocythemia: incidence, risk
factors, and effect of treatments. Haematologica 2008; 93: 372-380.
12. Mazzucconi MG, Redi R, Bernasconi S, et al. A long-term study of
young patients with essential thrombocythemia treated with anagrelide.
Haematologica 2004; 89: 1306-1313.
13. Fu R, Zhang L, Yang R. Paederiac essential thrombocythemia: clinical
and molecular features, diagnosis and treatment. Br J Haematol 2013;
163; 295-302.
14. Bildirici U, Celikyurt U, Ural E. Essential thrombocythemia: a case
of acute ST-segment elevation myocardial infarction in a young female.
Clin Cardiol 2009; 32: 104-105.
15. Lim YH, Lee YY, Kim JH, et al. Development of acute myocardial
infarction in a young female patient with essential thrombocythemia
treated with anagrelide: a case report. Korean J Hematol 2010; 45:
136-138.
16. Lata K, Madiraju N, Levitt L. JAK2 mutations and coronary ischemia.
N Engl J Med 2010; 363: 396-397.
17. Sibellas F, Schaaf M. Acute myocardial infarction and anagrelide.
Int J Cardiol 2013; 168: e50-e52.
18. Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A. Acute
coronary disease in essential thrombocythemia and polycythemia vera. J
Inter Med 1998; 244: 49-53.
19. Cella G, Marchetti M, Vianello F, et al. Nitric oxide derivatives
and soluble plasma selectins in patients with myeloproliferative
neoplasmas. Thronb Haemost 2010; 104: 151-156.
20. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and
blast transformation in molecularly annotated essential thrombocythemia,
polycythemia vera, and myelofibrosis. Blood 2014; 124: 2507-2513.
21. Hobbs CH, Manning H, Bennett C, et al. JAK2V617F leads to intrinsic
change in a knock-in mouse model of essential thrombocythemia. Blood
2013; 122: 3787-3797.
22. Harrison CN, Bareford D, Butt N, et al. Guideline for investigation
and management of adults and children presenting with a thrombocytosis.
Br J Haematol 2010; 149: 352-375.
23. Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with
hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET
study, a randomized controlled trial. Blood 2013; 121: 1720-1728.
24. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with
anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;
353: 33-45.
25. Ahluwalia M, Donovan H, Singh N, Butcher L, Erusalimski D.
Anagrelide represses GATA-1 and FOG-1 expression without interfering
with thrombopoietin receptor signal transduction. J Thromb Haemost 2010;
8: 2252-2261.
26. Lin GM, Chao TY, Wang WB. Acute coronary syndromes and anagrelide.
Int J Cardiol 2007; 117: e17-e19
27. Piccin A, Steurer M, Feistritzer C, et al. Observational
retrospective study of vascular modulator changes during treatment in
essential thrombocythemia. Transl Res: 2017; 184: 21-34.
28. Johnston H, Majewski H, Musgrave IF. Involvement of cyclic
nucleotides in prejunctional modulation of noradrenaline release in
mouse atria. Br J Pharmacol 1987; 91: 773-781.